Sanjay Popat/royalmarsden.nhs.uk
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared a post on X by AACR, adding:
“Wouldn’t it be great if FDA Oncology approvals were mutually approvable by Medicines and Healthcare products Regulatory Agency UK (MHRA)? Oh, hang on, the agreement already exists!”
Quoting AACR’s post:
“The US FDA approved a subcutaneous injection of the immunotherapy nivolumab with hyaluronidase for all previously approved indications of nivolumab to treat solid tumors.”
“FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection”
More posts featuring Sanjay Popat and AACR.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 23:12
Aug 25, 2025, 22:59
Aug 25, 2025, 22:10
Aug 25, 2025, 20:58
Aug 25, 2025, 20:44
Aug 25, 2025, 20:33
Aug 25, 2025, 19:54